• xxx

FAIVRE FINN, Corinne Professor (DAY ONE)

Professor of Thoracic Radiation Oncology at the UoM and Honorary Consultant Clinical Oncologist
The Christie NHS Foundation Trust.
“Developments in radiotherapy, within lung cancer”

Corinne Faivre-Finn, FRCR, MD, PhD, is a Professor of Thoracic Radiation Oncology at the University of Manchester and an Honorary Consultant Clinical Oncologist at The Christie NHS Foundation Trust with a special interest in lung cancer.  Prof Faivre-Finn trained in Paris until 1998 before accepting a post as a Consultant Clinical Oncologist at The Christie in Manchester, UK in 2001. As well as a busy clinical workload her primary research interests involve the development of practice changing multimodality treatments for stage III non small-cell lung cancer and limited stage small-cell lung cancer. She is also involved in the development of stereotactic radiotherapy, Intensity Modulated Radiotherapy, predictive modelling of radiotherapy outcomes based on population data and early phase trials combining thoracic radiotherapy and mechanism based therapies. She is an active member of the European Organisation for Research and Treatment of Cancer’s (EORTC) Radiotherapy and Lung groups and became the Radiotherapy Chair of the EORTC Lung Group in 2008. She is also a member of the ESTRO Clinical Committee. She is the Radiotherapy Research Lead for the CRUK Lung Cancer Centre of Excellence and the Manchester Cancer Research Centre, the Lung Tumour Site Coordinator for the Elekta/Philips MR linac Research Consortium and a member of the Advanced Radiotherapy Technologies Network (ARTNET) steering committee. She participates in the trial management group meetings of several UK/European lung cancer clinical trials and is the Chief Investigator of the international CONVERT study (limited-disease SCLC) as well as the following national trials; PIT (Mesothelioma), Isotoxic IMRT (stage III NSCLC), MEKRT (MEK inhibitor combined with thoracic radiotherapy in NSCLC) and PARIS (Pembroluzimab and combined with thoracic radiotherapy in NSCLC).